Drug Development - Targeting HER2 beyond Trastuzumab

被引：0
|
作者：
Spector, N. L. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-PL2-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PL2-1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting HER2 in breast cancer: beyond trastuzumab
    EP Winer
    Breast Cancer Research, 13
  • [2] Targeting HER2 in breast cancer: beyond trastuzumab
    Winer, F. P.
    BREAST CANCER RESEARCH, 2011, 13
  • [3] Targeting HER2 with Trastuzumab
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (11) : 22N - 22N
  • [4] HER2: Beyond trastuzumab
    Hudis, Clifford
    CANCER INVESTIGATION, 2007, 25 : 4 - 5
  • [5] Dual targeting of HER2 with lapatinib and trastuzumab
    Joensuu, Heikki
    LANCET ONCOLOGY, 2014, 15 (10): : 1050 - 1052
  • [6] Overcoming trastuzumab resistance using trastuzumab deruxtecan (T-DXd), a HER2 targeting antibody drug conjugate, in HER2 amplified gastric cancer.
    Park, Juin
    Jeong, Inhye
    Kang, Sun Kyoung
    Yu, Seo Young
    Kwon, Woo Sun
    Kim, Tae Soo
    Hwang, Jihyun
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Targeting HER2 beyond breast cancer
    Bhatnagar, Sanchita
    Tushir-Singh, Jogender
    MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (03):
  • [8] Targeting HER2 beyond progression in gastroesophageal cancer
    Sanoff, Hanna K.
    LANCET ONCOLOGY, 2017, 18 (05): : 562 - 564
  • [9] HER2 immunoreactivity and drug targeting in human retinoblastoma
    Seigel, Gail M.
    Mendoza, Pia
    Szalai, Eszter
    Shah, Dhaval K.
    Grossniklaus, Hans E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [10] Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
    Rassy, Elie
    Rached, Layal
    Pistilli, Barbara
    BREAST, 2022, 66 : 217 - 226
12345